Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI107782

Interrelations in the Oxidative Metabolism of Free Fatty Acids, Glucose, and Glycerol in Normal and Hyperlipemic Patients A COMPARTMENTAL MODEL

C. L. Malmendier, C. Delcroix, and M. Berman

Laboratory of Clinical Chemistry and Nuclear Medicine, Brussels University, Belgium, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Laboratory of Theoretical Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Malmendier, C. in: PubMed | Google Scholar

Laboratory of Clinical Chemistry and Nuclear Medicine, Brussels University, Belgium, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Laboratory of Theoretical Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Delcroix, C. in: PubMed | Google Scholar

Laboratory of Clinical Chemistry and Nuclear Medicine, Brussels University, Belgium, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Laboratory of Theoretical Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Berman, M. in: PubMed | Google Scholar

Published August 1, 1974 - More info

Published in Volume 54, Issue 2 on August 1, 1974
J Clin Invest. 1974;54(2):461–476. https://doi.org/10.1172/JCI107782.
© 1974 The American Society for Clinical Investigation
Published August 1, 1974 - Version history
View PDF
Abstract

Palmitate, glucose, and glycerol oxidation to CO2 have been investigated in the fasted state in ten normal subjects and nine patients (six hyperlipoproteinemias, one xanthomatosis, and two glycogenosis) after intravenous injection of [1-14C]palmitate, [1-14C]glucose, or [1-14C]glycerol in tracer amounts. The specific activities and concentrations of plasma palmitate, glycerol, or glucose and expired CO2 were measured at various intervals after the injection for a period of 24 h. All the studies were analyzed in terms of a multicompartment model describing the structure for each of the subsystems, the transfer of carbon label between subsystems, and the oxidation to CO2. A bicarbonate subsystem was also included in the model to account for its role in shaping the CO2 curves.

All the CO2 activity following a palmitate injection could be accounted for by a direct oxidative pathway from plasm FFA with the addition of a 20-min delay compartment. The same also applied to glucose, except that the delay compartment had a mean time of about 150 min. Only about a third of the injected glycerol was directly oxidized to CO2 from plasma; the delay time was about 4 min. Most of the remainder was converted to glucose.

In normals about 45% of the FFA is oxidized to CO2 directly. This constitutes about 30% of the total CO2 output. In hyperlipemia the CO2 output is nearly unchanged and the contribution from FFA is nearly the same. There is a considerable increase (factor of 2), however, in FFA mobilization, most of which is probably diverted to triglyceride synthesis.

The glucose and glycerol subsystems are roughly the same in normals and hyperlipemics. About 50% of glucose is oxidized by the direct pathways which accounts for about 35% of the CO2 output. Glycerol accounts for only 1.5% of the CO2 produced.

Major changes occurred in the glycerol and glucose subsystems in glycogenosis. The changes are consistent with the known deficiency in glucose-6-phosphatase in this disorder. There is a considerable reduction (factor of 2 or more) in the release of glucose to plasma (gluconeogenesis) and in the conversion of glycerol to glucose.

Despite the integration of the kinetics of the glucose, glycerol, and FFA subsystems over a 24-h period, 36% of the CO2 production was still unaccounted for in normals and 50% in hyperlipemics. Thus, some of the carbon must wind up in very slowly turning-over pools which supply CO2 through subsystems not covered in these studies (triglycerides, glycogen, amino acids, etc.).

All the modeling was carried out with the aid of the SAAM25 computer program.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 461
page 461
icon of scanned page 462
page 462
icon of scanned page 463
page 463
icon of scanned page 464
page 464
icon of scanned page 465
page 465
icon of scanned page 466
page 466
icon of scanned page 467
page 467
icon of scanned page 468
page 468
icon of scanned page 469
page 469
icon of scanned page 470
page 470
icon of scanned page 471
page 471
icon of scanned page 472
page 472
icon of scanned page 473
page 473
icon of scanned page 474
page 474
icon of scanned page 475
page 475
icon of scanned page 476
page 476
Version history
  • Version 1 (August 1, 1974): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts